By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Aldeyra Therapeutics 

15 New England Executive Park

Burlington  Massachusetts  01803  U.S.A.
Phone: 617-513-9882 Fax: N/A


Aldeyra Therapeutics is a biotechnology company devoted to improving lives by inventing, developing and commercializing products that treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules. The company's lead product, NS2, is an aldehyde trap in development for ocular and systemic inflammation, as well as for Sjögren-Larsson Syndrome and Succinic Semi-Aldehyde Dehydrogenase Deficiency, two inborn errors of aldehyde metabolism.




FOUNDERS: Thomas A. Jordan and John E. Dowling

CEO: Todd C. Brady

CMO: David J. Clark

CFO: Stephen Tulipano


Please click here for Aldeyra job opportunities..


Please click here for clinical trial information..

Key Statistics

Ownership: Public

Web Site: Aldeyra
Symbol: ALDX


Company News
Aldeyra (ALDX) Schedules Webcast And Conference Call For Full Year 2016 Financial Results 3/23/2017 12:20:26 PM
Aldeyra (ALDX) Launches The Aldeyra Registry For Patients With Sjögren-Larsson Syndrome 2/23/2017 12:26:59 PM
Aldeyra (ALDX) Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares 2/20/2017 7:19:58 AM
Aldeyra (ALDX) Prices Public Offering Of Common Stock 2/15/2017 10:38:35 AM
Aldeyra (ALDX) Proposes Public Offering Of Common Stock 2/14/2017 11:56:05 AM
Aldeyra (ALDX) Announces First Patient Enrolled In Allergic Conjunctivitis Phase IIb Clinical Trial 2/7/2017 8:43:47 AM
Aldeyra (ALDX) To Participate At The 2017 Rare Disease, Biopharma One-on-One Day 2/6/2017 10:33:54 AM
Aldeyra (ALDX) Release: Biotech Announces Clinical Development Update For Phase 3 Programs 1/25/2017 8:18:27 AM
Aldeyra (ALDX) Announces Third Quarter 2016 Financial Results 11/15/2016 10:57:16 AM
Aldeyra (ALDX) Announces Presentation Of Phase 2 Allergic Conjunctivitis Results At The 2016 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting 11/10/2016 7:10:17 AM